KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

AbbVie (ABBV) Income towards Parent Company (2016 - 2025)

AbbVie (ABBV) has disclosed Income towards Parent Company for 14 consecutive years, with $1.8 billion as the latest value for Q4 2025.

  • On a quarterly basis, Income towards Parent Company rose 7991.3% to $1.8 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $4.2 billion, a 1.24% decrease, with the full-year FY2025 number at $4.2 billion, down 1.24% from a year prior.
  • Income towards Parent Company was $1.8 billion for Q4 2025 at AbbVie, up from $188.0 million in the prior quarter.
  • In the past five years, Income towards Parent Company ranged from a high of $4.5 billion in Q1 2022 to a low of -$97.0 million in Q1 2023.
  • A 5-year average of $1.8 billion and a median of $1.5 billion in 2024 define the central range for Income towards Parent Company.
  • Peak YoY movement for Income towards Parent Company: surged 23694.12% in 2021, then tumbled 102.16% in 2023.
  • AbbVie's Income towards Parent Company stood at $4.0 billion in 2021, then tumbled by 38.89% to $2.5 billion in 2022, then plummeted by 52.99% to $1.2 billion in 2023, then tumbled by 101.98% to -$23.0 million in 2024, then soared by 7991.3% to $1.8 billion in 2025.
  • Per Business Quant, the three most recent readings for ABBV's Income towards Parent Company are $1.8 billion (Q4 2025), $188.0 million (Q3 2025), and $941.0 million (Q2 2025).